Table 1.
Modulation of TNF/IL-10 ratio by PCT-233 over time
| PCT-233 without LPS | PCT-233 with LPS | |||||
|---|---|---|---|---|---|---|
| Time (h) | 0 | 0·005% | 0·05% | 0 | 0·005% | 0·05% |
| 6 | 122·3 | 454·8 | 860·5 | 1176·3 | 723·4 | 909·4 |
| 18 | 19·7 | 24·2 | 85·9 | 155·9 | 42·9 | 88·4 |
| 24 | 15.6 | 22·0 | 18·8 | 59·0 | 26·7 | 20·9 |
| 48 | 13·6 | 4·7 | 2·3 | 21·6 | 3·4 | 2·5 |
| 72 | 22·7 | 1·5 | 2·3 | 12·1 | 1·7 | 2·3 |
| 96 | 70·5 | 2·1 | 0·8 | 7·8 | 2·9 | 1·2 |
| 120 | 28·5 | 2·0 | 1·0 | 6·7 | 2·8 | 1·4 |
Alveolar macrophages were treated with PCT-233 (0·005% and 0·05%) without and with LPS (10 ng/ml) for different periods of time (6, 18, 24, 48, 72, 96 and 120 h) and cell-free supernatants were tested for TNF and IL-10 content. The ratio was calculated by dividing TNF levels by IL-10 levels (ng/ml).